Basic Calan Sr Information

• INN (International Nonproprietary Name): Verapamil.
• Brand Names Available In United States: Calan, Calan SR, Verelan, Verelan PM, Covera-HS, and Tarka (combo with trandolapril).
• ATC Code: C08DA01 (Cardiovascular system; Calcium channel blockers; Phenylalkylamine derivatives; Verapamil).
• Forms & Dosages: Immediate-release tablets 40 mg, 80 mg, 120 mg; Extended-release tablets 120 mg, 180 mg, 240 mg; Extended-release capsules 120 mg, 180 mg, 240 mg.
• Manufacturers In United States: Pfizer (marketed as Calan SR), Abbott Laboratories, Knoll, Mylan, Sandoz, and other generics.
• Registration Status In United States: Approved by major regulators for hypertension, angina, and arrhythmias; prescription-only.
• OTC / Rx Classification: Prescription-only (Rx) in all major markets.

Key Findings From Recent Trials

Worried whether extended-release verapamil still stacks up in modern studies?

Recent randomized and real-world studies from 2022–2026 focused on extended-release verapamil formulations commonly marketed as Calan SR, Verelan, and Isoptin SR.

These analyses examined ambulatory blood pressure control, chronic stable angina outcomes, and maintenance therapy for supraventricular tachycardia (SVT).

Headline outcomes showed verapamil ER 180–240 mg once daily provided comparable 24-hour ambulatory blood pressure reductions to other nondihydropyridine agents.

Several cohort analyses reported superior nocturnal blood pressure smoothing with verapamil ER versus comparators, which may benefit patients with nighttime hypertension.

In chronic stable angina cohorts, verapamil ER reduced angina episodes and nitrate use at rates similar to diltiazem.

Verapamil produced fewer reflex tachycardia events than dihydropyridine calcium channel blockers in angina studies, consistent with its AV‑nodal effects.

Arrhythmia literature reinforced verapamil’s role in acute conversion and rate control for SVT when given intravenously or as immediate‑release oral dosing.

Extended‑release products were primarily used for maintenance therapy and to reduce dosing frequency and peak‑trough variability.

Main Outcomes

Verapamil ER provided effective 24‑hour blood pressure lowering with marked nocturnal benefit in several trials.

Angina control—frequency and nitrate consumption—was comparable to diltiazem in head‑to‑head analyses.

Rate control for atrial arrhythmias and maintenance suppression of SVT were effective with divided or ER dosing in registry data.

ER formulations improved adherence versus immediate‑release regimens, translating to more stable ambulatory readings in practice.

Safety Observations

Pooled safety signals confirmed expected adverse effects: constipation, ankle edema, dizziness, and bradycardia were most common.

Real‑world registries highlighted drug–drug interactions with CYP3A4 inhibitors, requiring dose adjustments and monitoring.

Regulatory surveillance during 2022–2026 found no new black‑box warnings or class withdrawals for marketed verapamil ER products.

Contraindications such as advanced AV block, severe hypotension, and severe heart failure remained central to prescribing decisions.

Clinical Mechanism Of Action

Want a simple explanation of how verapamil works?

Verapamil blocks L‑type calcium channels in heart and blood vessel muscle cells, reducing calcium entry and lowering heart workload while relaxing blood vessels.

Scientific Breakdown

Verapamil is a phenylalkylamine calcium channel blocker with preferential effects on cardiac conduction and contractility.

Cardiac Effects

Verapamil inhibits L‑type calcium channels in the sinoatrial and atrioventricular nodes, lowering conduction velocity and heart rate.

These actions produce negative chronotropy and negative inotropy, which makes verapamil useful for SVT conversion and ventricular rate control in some atrial arrhythmias.

Vascular Effects

Vascular smooth muscle relaxation from calcium channel blockade reduces peripheral resistance and afterload, contributing to blood pressure lowering and angina relief.

Pharmacokinetics

Verapamil is available as immediate‑release and extended‑release formulations, with ER preparations such as Calan SR, Verelan, and Covera‑HS designed to smooth plasma levels.

Typical ER oral doses for adults are 120–240 mg once daily for chronic conditions, while IR tablets are used for acute dosing and titration.

The drug undergoes hepatic metabolism with variable first‑pass effect, and extended‑release formulations help avoid large peak concentrations that increase side‑effect risk.

Clinically, ER formulations reduce reflex tachycardia and improve adherence compared with three‑times‑daily IR schedules.

Scope Of Approved & Off‑Label Use

Curious whether verapamil is indicated for your condition?

In the United States, verapamil products—Calan, Calan SR, Verelan, Covera‑HS—are FDA‑approved for hypertension, angina pectoris, and certain supraventricular arrhythmias.

Label guidance favors ER tablets (120–240 mg) for long‑term control of blood pressure and chronic angina, with immediate‑release products for acute situations.

Notable Off‑Label Trends

Specialist literature documents off‑label uses in select arrhythmia subtypes and, rarely, migraine prophylaxis under neurology supervision.

Pediatric use is uncommon and typically off‑label for refractory SVT, with weight‑based dosing handled by pediatric cardiology teams.

Clinicians often prefer ER products like Calan SR for once‑daily dosing and smoother plasma profiles, improving adherence in chronic therapy.

Brand availability differs by region—Isoptin SR is common in Europe and Canada, while Verapamilum appears in Eastern Europe—which influences prescribing and formulary choices.

Dosage Strategy

How should verapamil be dosed safely and effectively?

Adult ER dosing for hypertension and chronic angina usually ranges from 180 to 240 mg once daily, titrated based on response and tolerability.

General Dosing

Immediate‑release verapamil is commonly prescribed as 80–120 mg three times daily for angina or for acute oral therapy in arrhythmia management.

ER options—120, 180, 240 mg—allow once‑daily administration and more consistent plasma concentrations.

Condition‑Specific Dosing

Hypertension

Start with ER verapamil 180 mg once daily and titrate to 240 mg once daily as needed and tolerated.

Begin with lower doses in elderly patients or those with hepatic impairment and monitor blood pressure and heart rate closely.

Chronic Stable Angina

For angina, immediate‑release verapamil 80–120 mg three times daily or ER 180–240 mg once daily are standard regimens.

When coadministered with nitrates, monitor for additive hypotension and counsel patients on symptomatic lightheadedness.

Arrhythmias

Maintenance dosing for arrhythmias often ranges 240–320 mg/day in divided doses or as ER formulations for rate control.

Acute SVT conversion is typically managed with IV verapamil or immediate‑release oral dosing in a monitored setting by specialists.

Do not crush or chew ER tablets, including Calan SR strengths, as this destroys the extended‑release mechanism and risks dose dumping.

Safety Protocols

Worried about who should never take verapamil?

Contraindications

Absolute contraindications include severe hypotension (systolic <90 mmHg), second‑ or third‑degree AV block unless a pacemaker is present, sick sinus syndrome without pacing, known hypersensitivity, and severe heart failure.

These restrictions should be checked before prescribing and during routine monitoring.

Adverse Effects

Common side effects are constipation, dizziness, headache, ankle edema, nausea, and bradycardia.

Baseline checks should include heart rate, blood pressure, and ECG when conduction disease is suspected.

In elderly patients or those with hepatic impairment, begin at lower doses and titrate slowly while monitoring for hypotension and bradycardia.

Avoid abrupt discontinuation to reduce the risk of rebound symptoms.

Overdose produces severe hypotension and bradycardia and requires emergency support such as IV calcium, vasopressors, and pacing when indicated.

Interaction Mapping

Want to know what not to take with verapamil?

Food Interactions

ER tablets can be taken with or without food per product labeling, but grapefruit and grapefruit juice should be avoided because they inhibit CYP3A4 and raise verapamil exposure.

Drug Combinations To Avoid

Strong CYP3A4 inhibitors such as certain azole antifungals and macrolide antibiotics like clarithromycin can increase verapamil concentrations and require dose adjustments or alternative therapy.

Concomitant use with beta‑blockers, digoxin, or other AV‑node‑slowing agents increases the risk of severe bradycardia and AV block.

Other antihypertensives may have additive hypotensive effects; adjust doses and monitor blood pressure when starting or stopping agents.

Pharmacodynamic Risks

Combining verapamil with beta‑blockers should generally be avoided unless under cardiology supervision due to bradycardia and conduction disturbance risk.

Practical Steps

Always review the medication list for CYP3A4 inhibitors and digoxin interaction potential prior to initiating verapamil ER therapy.

Perform ECG monitoring when adding interacting agents that affect conduction or heart rate.

Patient Experience Analysis

What do patients report after switching to calan sr or another verapamil ER?

Surveys and patient‑reported outcome studies indicate better adherence with once‑daily ER formulations such as Calan SR and Verelan compared with thrice‑daily IR dosing.

Improved adherence often translates into more stable ambulatory blood pressure readings and fewer missed‑dose events.

Constipation and ankle edema are the most frequent complaints, and many patients accept these side effects when symptoms of angina and hypertension are controlled.

Older adults commonly report dizziness or lightheadedness, which often prompts dose reduction or slower titration.

Social forums and patient Q&A threads frequently ask about crushing ER tablets, brand differences (Calan SR vs Isoptin SR), and when to stop therapy.

Clinicians should counsel patients that ER tablets must not be crushed or chewed and should provide clear missed‑dose instructions to avoid accidental overdose.

Distribution & Pricing Landscape

How available is Calan SR and how much will it cost at my pharmacy?

Calan SR (Pfizer) plus multiple generics from manufacturers like Mylan and Sandoz dominate distribution in the United States.

Formulary placement often favors extended‑release formulations (120, 180, 240 mg) for chronic hypertension and angina management.

Generic verapamil ER tends to be less expensive and lowers out‑of‑pocket costs compared with brand Calan SR, with prices varying by strength and supply.

Supply chain and regional procurement practices influence availability and packaging; in some countries national registries like Romania’s ANMDMR determine local tenders and brands.

Prescription‑only status requires a clinician visit for a valid prescription, although some pharmacies offer mail order and 90‑day supplies to improve adherence.

In our online pharmacy, calan sr is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Should you consider diltiazem, amlodipine, or a beta‑blocker instead?

Primary alternatives include diltiazem (Cardizem/Tiazac), amlodipine (Norvasc), and beta‑blockers such as metoprolol and atenolol.

Each alternative has distinct strengths and tradeoffs related to AV nodal effects, peripheral vasodilation, and side‑effect profiles.

Comparison Table

Pros And Cons

Verapamil is an excellent choice when AV nodal suppression is desired and when reflex tachycardia should be avoided.

However, verapamil has important drug interactions and contraindications that may make diltiazem or dihydropyridines preferable for some patients.

Regulatory Status

Is verapamil regulated and where can I check official labeling?

Verapamil is approved by regulators including the US FDA and EMA for hypertension, angina, and certain arrhythmias, and remains a prescription‑only medicine.

Formulations such as Calan SR, Verelan, and Covera‑HS have specific labeling and dosing instructions for their ER strengths of 120, 180, and 240 mg.

Post‑market surveillance focuses on conduction disturbances and interactions, and no recent class-wide safety withdrawals were identified.

Clinicians should consult local product information and SPCs for brand‑specific guidance, especially when substituting generics or switching regions.

Consolidated FAQ

What Are The Questions Patients Ask Most?

• Can I crush Calan SR? No. Do not crush or chew extended‑release tablets because this destroys the ER mechanism and risks dose dumping.
• Is verapamil over‑the‑counter? No. Verapamil is prescription‑only in major markets.
• What Are Common Side Effects? Constipation, dizziness, ankle edema, nausea, and bradycardia are common and usually dose‑related.
• What If I Miss A Dose? Take the dose when remembered unless it is near the next scheduled dose; do not double the next dose.
• Can I Take Verapamil With A Beta‑Blocker? Use caution. The combination increases the risk of severe bradycardia and AV block and should be managed by cardiology.
• Pregnancy Or Nursing? Verapamil is generally avoided unless clearly needed; consult your healthcare provider for risk/benefit assessment.
• Signs Of Overdose? Severe hypotension, profound bradycardia, arrhythmia, or cardiac arrest require emergency care; supportive measures include IV calcium, vasopressors, and pacing.

Visual Guide

Want visual aids to understand dosing and safety at a glance?

Design four practical visuals for the article: a dose ladder infographic, a mechanism diagram, an interaction map, and a safety algorithm flowchart.

1) The Dose Ladder Infographic should show IR tablets (40/80/120 mg) and ER tablets/capsules (120/180/240 mg) with dosing frequency and clinical uses for hypertension, angina, and arrhythmia maintenance.

2) The Mechanism Diagram should depict L‑type calcium channel blockade in the SA/AV nodes and vascular smooth muscle with arrows for decreased conduction, contractility, and vasodilation.

3) The Interaction Map should list CYP3A4 inhibitors, grapefruit, beta‑blockers, and digoxin with clear risk icons and short guidance on monitoring.

4) The Safety Algorithm Flowchart should cover baseline checks (BP/HR/ECG), contraindications in red, monitoring cadence in amber, and overdose response steps (IV calcium, vasopressors, pacing) in red emergency boxes.

Ensure color coding for contraindications (red), monitoring (amber), and safe combinations (green), and include alt text and captions for accessibility.

Storage & Transport

How should verapamil tablets be stored at home or in pharmacies?

Store verapamil tablets, both IR and ER, at room temperature between 15–30°C and protect from moisture and heat.

Keep all medications out of reach of children and avoid storing tablets in bathrooms or near sinks where humidity is high.

ER tablets rely on intact coatings; crushing or repackaging into multi‑dose containers can compromise stability and release characteristics.

Pharmacies should rotate ER stock by expiry and avoid repackaging blistered ER tablets unless the manufacturer or regulatory guidance confirms stability.

Guidelines For Proper Use

What steps should a prescriber and patient follow for safe verapamil therapy?

Screen patients for contraindications before starting therapy, including assessing blood pressure, heart rate, and ECG when conduction disease is suspected.

Start with indication‑appropriate dosing—ER 180–240 mg once daily for hypertension and chronic angina; IR dosing for acute angina or supervised arrhythmia management.

Counsel patients to take ER tablets whole, avoid grapefruit juice, report dizziness or syncope, and never stop verapamil abruptly.

Reassess blood pressure and heart rate 1–2 weeks after initiation or dose changes and monitor for constipation and peripheral edema.

Coordinate therapy with cardiology when combining verapamil with beta‑blockers, digoxin, or other rhythm control drugs.

Document the brand and strength—such as Calan SR 120/180/240 mg—so the pharmacy dispenses a consistent product to support adherence.

Delivery Across United States

Closing Notes For Clinicians And Patients

Patients should be counseled on the balance of benefits and predictable risks of verapamil ER products such as Calan SR and Verelan.

Check for interactions with CYP3A4 inhibitors and drugs that slow AV conduction before initiating therapy.

Monitor blood pressure, heart rate, and symptoms within 1–2 weeks of starting or adjusting the dose.

For emergency concerns such as syncope, severe dizziness, or signs of overdose, seek immediate medical attention.

When in doubt about combinations with beta‑blockers, digoxin, or antiarrhythmic drugs, consult cardiology or refer to the product label for brand‑specific guidance.

Selecting ER formulations supports adherence and smoother plasma profiles, and generics provide cost savings while maintaining approved indications and dosing options.

Keep a record of the specific brand and strength dispensed—Calan SR 120/180/240 mg—so substitutions remain consistent and patients recognize their medication.